Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06331377 · ClinicalTrials.gov registry record
Clinical and Molecular Characteristics of Histiocytic Disorders
A clinical trial of Histiocytic Disorder, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 500
- Enrollment target
- 1
- Study location
NCT06331377: Recruiting study of Histiocytic Disorder, sponsored by Mayo Clinic.
NCT06331377 is a study of Histiocytic Disorder that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 500 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06331377, a study of Histiocytic Disorder, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being done to collect medical and personal histories as well as a samples of blood, other body fluid and/or tumor/disease tissue for current and future research studies on histiocytic disorders.
Primary Outcome
Biopsy samples will be analyzed for the presence of molecular markers associated with histiocytic disorders. Potential markers include BRAF V600E, cyclinD1, PD-L1, p16, and p53.6. For any test results that are actionable, patients will be notified and the results will be available in the electronic medical record.
Conditions Studied
Interventions
- OTHER Non-Interventional Study
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2017-07-27 |
| Est. Completion | 2027-07-31 |
What NCT06331377 shows while recruiting
NCT06331377 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Histiocytic Disorder appearing as the primary indexed condition, and to 1 intervention - of which Non-Interventional Study is the first listed.
NCT06331377 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT06331377 about?
NCT06331377 is a clinical study titled "Clinical and Molecular Characteristics of Histiocytic Disorders". This study is being done to collect medical and personal histories as well as a samples of blood, other body fluid and/or tumor/disease tissue for current and future research studies on histiocytic disorders.
What is the current status of trial NCT06331377?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2017-07-27. Estimated completion is 2027-07-31.
What conditions does trial NCT06331377 study?
This clinical trial studies the following conditions: Histiocytic Disorder.
What interventions are being tested in trial NCT06331377?
The interventions under investigation include: Non-Interventional Study (OTHER).
Who is sponsoring clinical trial NCT06331377?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06331377 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI